Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
LP002 is a highly selected recombinant humanized anti-PD-L1 monoclonal antibody. This is a
single-arm, multicenter study to evaluate the efficacy and safety of LP002 in combination
with chemotherapy in patients with extensive stage samll cell lung cancer.